- Cosmo Pharmaceuticals NV Investor Day TranscriptMar 20, 2024
- Full Year 2023 Cosmo Pharmaceuticals NV Earnings Call TranscriptMar 20, 2024CHF66.5 (+1.06%)Earnings
- Half Year 2023 Cosmo Pharmaceuticals NV Earnings Call TranscriptJul 26, 2023CHF45.95 (-3.67%)Earnings
- Full Year 2022 Cosmo Pharmaceuticals NV Earnings Call TranscriptMar 23, 2023CHF55.5 (+3.35%)Earnings
- Half Year 2022 Cosmo Pharmaceuticals NV Earnings Call TranscriptJul 28, 2022CHF50.9 (+6.26%)Earnings
- Full Year 2021 Cosmo Pharmaceuticals NV Earnings Call TranscriptMar 23, 2022CHF65.9 (+12.07%)Earnings
- Half Year 2021 Cosmo Pharmaceuticals NV Earnings Call TranscriptJul 30, 2021CHF85 (-2.52%)Earnings
- Cosmo Pharmaceuticals NV to Discuss GI Geniusâ„¢ Call (Q&A Session) TranscriptMay 04, 2021
- Full Year 2020 Cosmo Pharmaceuticals NV Earnings Call TranscriptMar 26, 2021CHF86.8 (+0.58%)Earnings
- Half Year 2020 Cosmo Pharmaceuticals NV Earnings Call TranscriptJul 30, 2020CHF87 (-3.12%)Earnings
- Full Year 2019 Cosmo Pharmaceuticals NV Earnings Call TranscriptApr 03, 2020CHF64.9 (+1.41%)Earnings
- Half Year 2019 Cosmo Pharmaceuticals NV Earnings Call TranscriptJul 30, 2019CHF88 (+4.76%)Earnings
- Cosmo Pharmaceuticals NV R&D Day TranscriptMay 08, 2019
- Full Year 2018 Cosmo Pharmaceuticals NV Earnings Call TranscriptMar 29, 2019CHF82.85 (+6.97%)Earnings
Full Year 2020 Cosmo Pharmaceuticals NV Earnings Call Transcript
Ladies and gentlemen, welcome to the Cosmo Pharmaceuticals 2020 Results and 2021 Outlook Conference Call. I am Alice, the Chorus Call operator.
(Operator Instructions)
And the conference is being recorded.
(Operator Instructions)
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to and over to the management team of Cosmo Pharmaceuticals. Please go ahead.
Good afternoon, everyone. This is Alessandro Della Chà , the CEO of Cosmo. And on the call with me also Niall Donnelly, the CFO. Thanks for joining. 2020 has been a very interesting year for Cosmo. Notwithstanding the pandemic, we have had major advancements on basically all fronts. We've seen a streak of approval. We've seen the return to operating profit, and we have seen the return to positive cash inflow from operating activities.
So our outlook now looks very different from 2019, and we're very happy that we've been able to reach
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)